Jounce Therapeutics' core business segment revolves around the research and development of innovative cancer immunotherapies. This involves the discovery and preclinical/clinical development of novel therapeutic candidates designed to harness the power of the immune system to fight cancer. Key R&D activities include identifying and validating novel immuno-oncology targets, generating therapeutic antibodies and other biologics, and conducting preclinical studies to assess efficacy and safety. Technologies employed include antibody engineering, cell-based assays, and in vivo models. The therapeutic focus is on various solid tumors, with the goal of improving patient outcomes through targeted immunomodulation. This segment aims to establish Jounce as a leader in the immuno-oncology space by developing first-in-class or best-in-class therapies.